GlassScriptPhysician profile
Faisal N Masud
NPI 1023054525
$154,818.96
in general payments reported to CMS, 2019-2025
16 companies · $14K in 2025
The $14K reported for 2025 was more than what 97% of Critical Care Medicine (Anesthesiology) providers received nationally (typical 2025 total: $97.90).
See the full distribution for Critical Care Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,917 · 2020: $4,750 · 2021: $22K · 2022: $22K · 2023: $45K · 2024: $39K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $57K · Consulting Fee: $30K · Travel and Lodging: $8,867 · Food and Beverage: $2,862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $57,055.00 |
| Consulting Fee | $29,831.50 |
| Travel and Lodging | $8,866.63 |
| Food and Beverage | $2,862.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $59,589.61 | 2022-2024 | Andexxa |
| Teleflex LLC | $30,345.24 | 2020-2025 | Arrow |
| Gilead Sciences, INC. | $23,929.28 | 2024 | Veklury |
| Alexion Pharmaceuticals, INC. | $16,130.41 | 2021-2022 | |
| Btg International INC. | $10,452.47 | 2025 | |
| Portola Pharmaceuticals, LLC | $8,618.43 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $2,965.27 | 2019-2025 | Giapreza |
| C. R. Bard, INC. & Subsidiaries | $1,258.33 | 2021 | |
| Allergan, INC. | $1,000.00 | 2020 | |
| Merck Sharp & Dohme LLC | $230.54 | 2023-2025 | Recarbrio, Zerbaxa |
| Boston Scientific Corporation | $150.87 | 2024 | |
| Melinta Therapeutics, LLC | $78.65 | 2023 | Vabomere |
| Mindray Ds USA, INC. | $36.60 | 2023 | Te7 Max, Te X |
| Medtronic Vascular, INC. | $33.26 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faisal Masud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.